OBJECTIVE: To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc). METHODS: The Scleroderma Clinical Trials Consortium (SCTC) conducted a structured, 3-round Delphi exercise to reach consensus on a core set of measures for clinical trials of SSc. Round 1 asked the SCTC investigators to list items in 11 pre-defined domains (skin, musculoskeletal, cardiac, pulmonary, cardio-pulmonary, gastrointestinal, renal, Raynaud phenomenon and digital ulcers, health-related quality of life and function, global health, and biomarkers) for SSc clinical trials. Round 2 asked respondents to rate the importance of the chosen items and was followed by a meeting, during which the Steering Committee discussed the feasibility, reliability, redundancy and validity of the items. Round 3 sought to obtain broader consensus on the core set measures. Members also voted on items that had data on feasibility but lacked data on reliability and validity, but may still be useful research outcome measures for future trials. RESULTS: A total of 50 SCTC investigators participated in round 1, providing 212 unique items for the 11 domains. In all, 46 (92%) participants responded in round 2 and rated 177 items. The ratings of 177 items were reviewed by the Steering Committee and 31 items from the 11 domains were judged to be appropriate for inclusion in a 1-year multi-centre clinical trial. In total, 40 SCTC investigators completed round 3 and ranked 30 of 31 items as acceptable for inclusion in the core set. The Steering Committee also proposed 14 items for a research agenda. CONCLUSION: Using a Delphi exercise, we have developed a provisional core set of measures for assessment of disease activity and severity in clinical trials of SSc.
OBJECTIVE: To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc). METHODS: The Scleroderma Clinical Trials Consortium (SCTC) conducted a structured, 3-round Delphi exercise to reach consensus on a core set of measures for clinical trials of SSc. Round 1 asked the SCTC investigators to list items in 11 pre-defined domains (skin, musculoskeletal, cardiac, pulmonary, cardio-pulmonary, gastrointestinal, renal, Raynaud phenomenon and digital ulcers, health-related quality of life and function, global health, and biomarkers) for SSc clinical trials. Round 2 asked respondents to rate the importance of the chosen items and was followed by a meeting, during which the Steering Committee discussed the feasibility, reliability, redundancy and validity of the items. Round 3 sought to obtain broader consensus on the core set measures. Members also voted on items that had data on feasibility but lacked data on reliability and validity, but may still be useful research outcome measures for future trials. RESULTS: A total of 50 SCTC investigators participated in round 1, providing 212 unique items for the 11 domains. In all, 46 (92%) participants responded in round 2 and rated 177 items. The ratings of 177 items were reviewed by the Steering Committee and 31 items from the 11 domains were judged to be appropriate for inclusion in a 1-year multi-centre clinical trial. In total, 40 SCTC investigators completed round 3 and ranked 30 of 31 items as acceptable for inclusion in the core set. The Steering Committee also proposed 14 items for a research agenda. CONCLUSION: Using a Delphi exercise, we have developed a provisional core set of measures for assessment of disease activity and severity in clinical trials of SSc.
Authors: P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold Journal: Arthritis Rheum Date: 2012-10
Authors: M H Buch; C P Denton; D E Furst; L Guillevin; L J Rubin; A U Wells; M Matucci-Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black; J R Seibold Journal: Ann Rheum Dis Date: 2006-07-25 Impact factor: 19.103
Authors: Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays Journal: Qual Life Res Date: 2007-04-03 Impact factor: 4.147
Authors: Daniel Furst; Dinesh Khanna; Marco Matucci-Cerinic; Philip Clements; Virginia Steen; Janet Pope; Peter Merkel; Ivan Foeldvari; James Seibold; David Pittrow; Richard Polisson; Vibeke Strand Journal: J Rheumatol Date: 2007-05 Impact factor: 4.666
Authors: Christopher P Denton; Peter A Merkel; Daniel E Furst; Dinesh Khanna; Paul Emery; Vivien M Hsu; Nancy Silliman; James Streisand; John Powell; Anita Akesson; John Coppock; Frank van den Hoogen; Ariane Herrick; Maureen D Mayes; Douglas Veale; Joanna Haas; Stephen Ledbetter; Joseph H Korn; Carol M Black; James R Seibold Journal: Arthritis Rheum Date: 2007-01
Authors: Dinesh Khanna; Mansoor Ahmed; Daniel E Furst; Shaari S Ginsburg; Grace S Park; Richard Hornung; Joel Tsevat Journal: Arthritis Rheum Date: 2007-02-15
Authors: Rachel K Hoyles; Ross W Ellis; Jessica Wellsbury; Belinda Lees; Pauline Newlands; Nicole S L Goh; Christopher Roberts; Sujal Desai; Ariane L Herrick; Neil J McHugh; Noeleen M Foley; Stanley B Pearson; Paul Emery; Douglas J Veale; Christopher P Denton; Athol U Wells; Carol M Black; Roland M du Bois Journal: Arthritis Rheum Date: 2006-12
Authors: Peter A Merkel; Nancy P Silliman; Christopher P Denton; Daniel E Furst; Dinesh Khanna; Paul Emery; Vivien M Hsu; James B Streisand; Richard P Polisson; Anita Akesson; John Coppock; Frank van den Hoogen; Ariane Herrick; Maureen D Mayes; Douglas Veale; James R Seibold; Carol M Black; Joseph H Korn Journal: Arthritis Rheum Date: 2008-05-15
Authors: Dinesh Khanna; Ron D Hays; Grace S Park; Yolanda Braun-Moscovici; Maureen D Mayes; Terry A McNearney; Vivien Hsu; Philip J Clements; Daniel E Furst Journal: Arthritis Rheum Date: 2007-10-15
Authors: P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold Journal: Arthritis Rheum Date: 2012-10
Authors: Beth Wallace; Suzanne Kafaja; Daniel E Furst; Veronica J Berrocal; Peter A Merkel; James R Seibold; Maureen D Mayes; Dinesh Khanna Journal: Rheumatology (Oxford) Date: 2015-02-09 Impact factor: 7.580
Authors: Dinesh Khanna; Daniel E Furst; Yannick Allanore; Sangmee Bae; Vijay Bodukam; Philip J Clements; Maurizio Cutolo; Laszlo Czirjak; Christopher P Denton; Oliver Distler; Ulrich A Walker; Marco Matucci-Cerinic; Ulf Müller-Ladner; James R Seibold; Manjit Singh; Alan Tyndall Journal: Rheumatology (Oxford) Date: 2014-08-13 Impact factor: 7.580
Authors: Dinesh Khanna; Chi-Hong Tseng; Daniel E Furst; Philip J Clements; Robert Elashoff; Michael Roth; David Elashoff; Donald P Tashkin Journal: Rheumatology (Oxford) Date: 2009-09-23 Impact factor: 7.580
Authors: John D Pauling; Tracy M Frech; Michael Hughes; Jessica K Gordon; Robyn T Domsic; Marina E Anderson; Francesca Ingegnoli; Neil J McHugh; Sindhu R Johnson; Marie Hudson; Francesco Boin; Voon H Ong; Marco Matucci-Cerinic; Nezam Altorok; Marina Scolnik; Mandana Nikpour; Ankoor Shah; Janet E Pope; Dinesh Khanna; Ariane L Herrick Journal: J Scleroderma Relat Disord Date: 2018-05-24